Mineralocorticoid receptor signaling affects therapeutic effect of enzalutamide

Current treatment strategies for advanced prostate cancer

(2017) Kazumasa Komura et al.   INTERNATIONAL JOURNAL OF UROLOGY

Amiloride Is Effective in the Management of Abiraterone-Induced Mineralocorticoid Excess Syndrome without Interfering with Its Antineoplastic Activity

(2017) Francesca Bedussi et al.   PHARMACOLOGY

Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer

(2016) Masaki Shiota et al.   INTERNATIONAL JOURNAL OF UROLOGY

Potential Role for YB-1 in Castration-Resistant Prostate Cancer and Resistance to Enzalutamide Through the Androgen Receptor V7

(2016) Masaki Shiota et al.   JNCI-Journal of the National Cancer Institute

Potential Role for YB-1 in Castration-Resistant Prostate Cancer and Resistance to Enzalutamide Through the Androgen Receptor V7

(2016) Masaki Shiota et al.   JNCI-Journal of the National Cancer Institute

Taxane Chemotherapy for Hormone-Naïve Prostate Cancer with Its Expanding Role as Breakthrough Strategy

(2016) Masaki Shiota et al.   Frontiers in Oncology

Androgen–glucocorticoid interactions in the era of novel prostate cancer therapy

(2015) Sujata Narayanan et al.   Nature Reviews Urology

Inhibition of RSK/YB-1 signaling enhances the anti-cancer effect of enzalutamide in prostate cancer

(2014) Masaki Shiota et al.   PROSTATE

Inhibition of the androgen receptor by mineralocorticoids at levels physiologically achieved in serum in patients treated with abiraterone acetate

(2014) W Kim et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Glucocorticoid Receptor Activity Contributes to Resistance to Androgen-Targeted Therapy in Prostate Cancer

(2014) Masis Isikbay et al.   Hormones & Cancer

Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade

(2013) Vivek K. Arora et al.   CELL

Inhibition of Protein Kinase C/Twist1 Signaling Augments Anticancer Effects of Androgen Deprivation and Enzalutamide in Prostate Cancer

(2013) M. Shiota et al.   CLINICAL CANCER RESEARCH

Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining with MDV3100

(2012) J. Richards et al.   CANCER RESEARCH

Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression

(2011) M. Shiota et al.   ENDOCRINE-RELATED CANCER

Differential expression of determinants of glucocorticoid sensitivity in androgen-dependent and androgen-independent human prostate cancer cell lines

(2009) Andrea Dovio et al.   JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY

Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression

(2009) M Shiota et al.   ONCOGENE